News | Prostate Cancer | September 14, 2015

New Prostate Imaging Agent Improves Detection of Metastatic Cancer Cells

Study results show cancer detected in half of subjects with new agent, compared to none with conventional imaging

ImaginAb, prostate imaging agent, prostate cancer, World Molecular Imaging Conference, molecular imaging, PET

September 14, 2015 — ImaginAb Inc. has released interim results from a Phase 2 clinical trial of IAB2M, the company's proprietary imaging agent for management of prostate cancer. IAB2M demonstrated superior performance in detecting disease compared with ProstaScint and conventional imaging technologies including computed tomography (CT) scans, magnetic resonance imaging (MRI) scans and bone scans. In addition, the agent accurately detected metastatic disease in normal-sized lymph nodes, overcoming a major limitation of existing technologies and addressing a key clinical need.

The trial data were presented at the World Molecular Imaging Congress 2015 in Honolulu, Hawaii.

"Accurate detection of extra-prostatic disease in high-risk prostate cancer is critical for providing the best possible care to patients undergoing radical prostatectomy," said Robert Reiter, M.D., co-director of the Genitourinary Oncology Program in UCLA's Jonsson Cancer Center. "However, conventional imaging fails to detect metastatic disease in up to 50 percent of high-risk prostate cancer patients. As our data show, ImaginAb's imaging agent provides a whole-body picture of disease activity, with the potential to change patient management and guide the course of care for best possible outcomes."

Results include the first nine of 20 patients in an ongoing, open-label, Phase 2, single-center trial. Patients received IAB2M intravenously prior to a whole-body positron emission tomography (PET) scan. The agent detected disease in lymph nodes of three of six subjects, later confirmed positive for metastasis at surgery. This is in stark contrast to ProstaScint and conventional imaging, which did not detect metastasis in lymph nodes in any of those subjects.

For more information: www.imaginab.com

Related Content

Doctor-Patient Discussions Neglect Potential Harms of Lung Cancer Screening
News | Lung Cancer | August 15, 2018
August 15, 2018 — Although national guidelines advise doctors to discuss the benefits and harms of...
Exact Imaging Becomes UroGPO Imaging Partner
News | Ultrasound Imaging | August 10, 2018
Exact Imaging announced that it has become a UroGPO Imaging Partner, joining the North American urology-specific group...
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women
News | Women's Health | August 07, 2018
Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form...
Cardiac Monitoring a Higher Priority for High-Risk Breast Cancer Patients
News | Cardio-oncology | August 07, 2018
August 7, 2018 — While heart failure is an uncommon complication of...
Novel PET Imaging Method Could Track and Guide Type 1 Diabetes Therapy
News | PET Imaging | August 03, 2018
Researchers have discovered a new nuclear medicine test that could improve care of patients with type 1 diabetes. The...
computed tomography brain scan

Image courtesy of Pixabay

News | Clinical Trials | July 19, 2018
The use of computed tomography (CT) scans has increased dramatically over the last two decades. CT scans greatly...
CT Decision Instrument Reliably Guides Pediatric Blunt Trauma imaging Decisions

This is a four-site prospective observational cohort. Image courtesy of Kirsty Challen, B.Sc., MBCHB, MRES, Ph.D., Lancashire Teaching Hospitals, United Kingdom.

News | Clinical Decision Support | July 18, 2018
A new study finds The Pediatric NEXUS Head Computed Tomography (CT) Decision Instrument (DI) reliably identifies blunt...
Study Points to Need for Performance Standards for EHR Usability and Safety
News | Electronic Medical Records (EMR) | July 18, 2018
A novel new study provides compelling evidence that the design, development and implementation of electronic health...
Artificial Intelligence Provides Faster, Clearer MRI Scans

A new artificial-intelligence-based approach to image reconstruction, called AUTOMAP, yields higher quality images from less data, reducing radiation doses for CT and PET and shortening scan times for MRI. Shown here are MR images reconstructed from the same data with conventional approaches, at left, and AUTOMAP, at right. Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital

News | Artificial Intelligence | July 17, 2018
A research team with funding from the National Institute for Biomedical Imaging and Bioengineering (NIBIB) has...
Overlay Init